Johnson & Johnson (NYSE:JNJ) is Community Bank & Trust Waco Texas’ 3rd Largest Position

Community Bank & Trust Waco Texas grew its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 0.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 56,101 shares of the company’s stock after purchasing an additional 74 shares during the quarter. Johnson & Johnson makes up 3.3% of Community Bank & Trust Waco Texas’ portfolio, making the stock its 3rd biggest position. Community Bank & Trust Waco Texas’ holdings in Johnson & Johnson were worth $9,958,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of JNJ. Taylor & Morgan Wealth Management LLC raised its position in Johnson & Johnson by 1.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after purchasing an additional 57 shares during the last quarter. Circle Wealth Management LLC raised its position in Johnson & Johnson by 0.5% in the 1st quarter. Circle Wealth Management LLC now owns 11,326 shares of the company’s stock valued at $2,007,000 after purchasing an additional 59 shares during the last quarter. Red Wave Investments LLC raised its position in Johnson & Johnson by 2.0% in the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after purchasing an additional 59 shares during the last quarter. Argus Investors Counsel Inc. raised its position in Johnson & Johnson by 0.6% in the 2nd quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after purchasing an additional 61 shares during the last quarter. Finally, Alta Capital Management LLC raised its position in shares of Johnson & Johnson by 0.4% during the second quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock worth $2,808,000 after acquiring an additional 61 shares during the last quarter. Institutional investors own 68.59% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at $18,864,202. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at $18,864,202. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Hait sold 15,000 shares of the company’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $171.55, for a total value of $2,573,250.00. Following the sale, the insider now owns 80,236 shares in the company, valued at approximately $13,764,485.80. The disclosure for this sale can be found here. Insiders sold 212,646 shares of company stock valued at $36,791,022 over the last three months. Company insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on JNJ. StockNews.com began coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Raymond James dropped their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Atlantic Securities dropped their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Bank of America dropped their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Finally, Sanford C. Bernstein dropped their price objective on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $181.33.

Johnson & Johnson Stock Up 0.1 %

NYSE:JNJ opened at $177.01 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The stock has a market cap of $462.79 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 3.49 and a beta of 0.57. The stock has a 50-day moving average price of $168.35 and a two-hundred day moving average price of $171.28. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.60 earnings per share. As a group, equities analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson announced that its board has initiated a stock repurchase program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 1.2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. The ex-dividend date is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.55%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.